<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573052</url>
  </required_header>
  <id_info>
    <org_study_id>UU40574</org_study_id>
    <nct_id>NCT01573052</nct_id>
  </id_info>
  <brief_title>Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal</brief_title>
  <official_title>Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Salt Lake City Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Salt Lake City Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind controlled trial comparing treatment outcomes between
      chloriazepide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent
      veteran subjects. The objective of this trial is to compare the safety and effectiveness of
      these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin
      over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence,
      withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and
      alcohol craving.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PENN Alcohol Craving Scale</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ataxia</measure>
    <time_frame>1 week</time_frame>
    <description>Brief neurological exam for coordination including assessment of stance, tandem gait, romberg test, pronator drift, toe and heel walk, rapid-alternating-movements, and point-to-point movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal assessment scale</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Chlordiazepoxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlordiazepoxide</intervention_name>
    <description>25mg qid x 3 days then tapered over 3 days</description>
    <arm_group_label>Chlordiazepoxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>300mg qid x 3 days then tapered over 3 days</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alcohol dependent at risk for withdrawal symptoms

        Exclusion Criteria:

          -  Benzodiazepine dependent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher J Stock, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salt Lake VA Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George E Wahlen VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Salt Lake City Health Care System</investigator_affiliation>
    <investigator_full_name>Christopher J. Stock, PharmD</investigator_full_name>
    <investigator_title>Investigational pharmacist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Chlordiazepoxide</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 18, 2012</submitted>
    <returned>January 23, 2013</returned>
    <submitted>January 23, 2013</submitted>
    <returned>February 27, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

